SK's new thing

Branching out from its high-net worth investor base, SK Capital Partners tapped institutional investors for $500 million to close out its third fund. The private equity firm also is adding healthcare to its focus areas in chemicals and specialty materials.

SK's expansion into the healthcare sector stems from the recent addition of two managing partners, Aaron Davenport and James Marden, who joined the firm last year from Arsenal Capital Partners...